Objective: To evaluate the effects of different stroke volume variation (SVV) targets on endothelial glycocalyx (EG) shedding. Study Design: Randomised controlled trial. Place and Duration of Study: Department of Anaesthesiology, Peking University International Hospital, Beijing, China, from February to June 2018. Methodology: Patients undergoing elective retroperitoneal tumour resection were assigned to one of two groups. SVV 9% group (n=40), who received a more traditional (liberal) uid therapy with SVVd 9%; and the SVV 14% group (n=40), received restrictive uid therapy with SVV d 14%. Patients serum concentrations of syndecan-1 (SDC-1), interleukin-6 (IL-6) and tumour necrosis factor-± (TNF-±) were measured at the time that patients entered the operating theatre; at 1- and 4-hours following initiation of the surgery; and at 24- and 72-hours post-surgery. Postoperative complications, and one-year survival rates were also noted. Results: Perioperative serum SDC-1, IL-6 and TNF-± concentrations were significantly elevated in both groups, which were more pronounced in SVV 9% (p = 0.028, <0.001, and <0.001 respectively). A positive correlation was observed between SDC-1 and TNF-±, L-6, and infusion volume, respectively. Postoperative complications, including fever and blood transfusion, were more aggravated in SVV 9% than those in SVV 14% (80% vs. 59%, and 45% vs. 23.1%, both p <0.05). However, no significant difference in the one-year survival rate was observed. Conclusion: Using SVV 14% as a target for guiding uid therapy in elective retroperitoneal tumour resection was associated with reduced perioperative glycocalyx shedding, ameliorated inflammatory response, and reduced postoperative complications.